Shellworks

Executive Summary

Shellworks is a UK-based synthetic biology company developing a proprietary platform that engineers microbes to produce self-assembling, customizable micro- and nano-structures for drug delivery and biomaterial fabrication. Founded in 2019, the company leverages synthetic biology to program bacteria to encapsulate therapeutic cargo in targeted, programmable shells. This platform has broad applications in targeted drug delivery, probiotics, and sustainable materials, offering potential advantages in stability, biocompatibility, and scalability over conventional delivery systems. Shellworks operates at the platform stage, with its technology still in development but poised to address key challenges in precision medicine and biologics delivery. The company has raised undisclosed funding and operates with a small team (1-50 employees) in London. While still preclinical, Shellworks' platform could attract partnerships with pharmaceutical companies seeking novel delivery solutions. Key risks include the technical challenges of engineering stable microbial systems, regulatory hurdles for living therapeutics, and competition from other drug delivery platforms. If successful, Shellworks could become a key enabler for next-generation biologics. Conviction is moderate given the early stage and lack of public data, but the platform's versatility justifies monitoring.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round70% success
• Q2 2027Partnership with Major Pharma for Targeted Delivery40% success
• Q1 2027Preclinical Proof-of-Concept Data Publication60% success